<DOC>
	<DOCNO>NCT00417703</DOCNO>
	<brief_summary>This study quantify intraocular pressure elevation immediate time period follow intravitreous injection . With widespread use intravitreous injection patient may require several injection per year , important document sudden increase intraocular pressure , include maximum intraocular pressure time require intraocular pressure return baseline . This data may useful stimulate additional study evaluate long term ocular effect repeat intravitreous injection . We hypothesize intraocular pressure increase significantly follow intravitreous injection return baseline initial thirty minute follow ranibizumab injection .</brief_summary>
	<brief_title>Intraocular Pressure Immediately Following Intravitreous Injection Ranibizumab</brief_title>
	<detailed_description>We assess trend intraocular pressure immediately follow intravitreal injection ranibizumab 0.5 mg ( 0.05 mL ) take serial intraocular pressure reading every five minute thirty minute injection . This study prospective descriptive data collection consist measure intraocular pressure immediately follow intraocular injection , 5 , 10 , 15 , 20 , 25 , 30 minute follow injection ranibizumab 0.5 mg .</detailed_description>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Male Female Patients &gt; 18 year age 2 . Patients document choroidal neovascular membrane fluorescein angiogram and/or optical coherence tomography 3 . Requiring treatment maintenance therapy choroidal neovascular membrane 4 . Able willing provide write informed consent 1 . History arterial occlusive disease eye . 2 . History advance glaucoma .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Intraocular Pressure</keyword>
	<keyword>Intravitreous Injection</keyword>
	<keyword>Ranibizumab</keyword>
</DOC>